Place of loop diurethics in treatment of chronic heart failure


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents the modern concepts of the place of loop diuretics in the treatment of chronic heart failure. The theoretical and evidential base for the use of torasemide in the treatment of heart failure and its wider use is discussed.

Full Text

Restricted Access

About the authors

Svetlana N. Tolpygina

State scientific research center for preventive medicine

Email: stolpygina@gnicpm.ru
MD, leading researcher of the Department of preventive pharmacotherapy

References

  1. McMurray J.J., Adamopoulos S., Anker S.D. et al. ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2012,33:1787-847.
  2. Heidenreich P.A., Albert N.M., Aller L.A. et al. American Heart Association Advocacy Coordinating Committee; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Stroke Council. Forecasting the impact of heart failure in the United State: a policy statement from the American Heart Association. Circ. Heart Fail. 2013;6(3):606-9.
  3. Федеральные клинические рекомендации по диагностике и лечению хронической и острой сердечной недостаточности. М., 2013 [Federal clinical recommendations on diagnostics and treatment of chronic and acute heart failure. Moscow, 2013 (in Russ.)]
  4. Агеев Ф.Т., Даниелян М.О., Мареев В.Ю. и др. Больные с хронической сердечной недостаточностью в российской амбулаторной практике: особенности контингента, диагностики и лечения (по материалам исследования ЭПОХА-ОХСН. Сердечная недостаточность. 2004; 5(1):4-7. [Ageev F.T., Danielyan М.О., Mareev V.Yu. et al. Patients with chronic heart failure in the Russian ambulatory practice: contingent features, diagnosis and treatment (studies of EPOKHA-О-KHSN. Heart failure. 2004;5(1):4-7 (in Russ.)]
  5. Бойцов С.А., Лукьянов М.М., Якушин C.C., Марцевич С.Ю. и др. Амбулаторно-поликлинический регистр РЕКВАЗА: данные проспективного наблюдения, оценка риска и исходы у больных кардиоваскулярными заболеваниями. Кардиоваскулярная терапия и профилактика, 2015;14(1):53-62. [Bojtsov S.A., Lukyanov M. M., Yakushin C.S., Martsevich S.Yu. et al. Out-patient and polyclinic register REKVAZA: data of prospective supervision, assessment of risk and outcomes at patients with cardiovascular diseases. Cardiovascular therapy and prevention, 2015;14(1):53-62 (in Russ.)]
  6. Посненкова О.М., Киселев А.Р., Коротин А.С. и др. Публичный отчет о качестве медицинской помощи больным со стабильной ишемической болезнью сердца и хронической сердечной недостаточностью в 2013 году: данные регистра ишемической болезни сердца и хронической сердечной недостаточности по г. Саратову. ISSN 2313-0318, Кардио-ИТ 2014; 1: 0402 1/9 doi: 10.15275/cardioit.2014.0402 [Posnenkova O. M., Kiselyov A.R. et al. The public report on quality of medical care by the patient with stable coronary heart disease and chronic heart failure in 2013: data of the register of coronary heart disease and chronic heart failure on Saratov. ISSN 2313-0318, Kardio-IT 2014; 1: 0402 1/9 doi: 10.15275/cardioit.2014.0402 (in Russ.)]
  7. Панов А.В., Абесадзе И.Т., Алугишвили М.З. и др. Регистр больных, перенесших операцию АКШ при ИБС стабильного течения (программа РИКОШЕТ). Артериальная гипертензия. 2014;20(6):568-77. [Panov A.V., Abesadze I.T., Alugishvili M.Z. et al. The register of the patients who have undergone operation AKSh at ischemic heart disease of stable current (RICOCHET program). Arterial hypertension. 2014; 20(6):568-77 (in Russ.)]
  8. Шальнова С.А., Оганов Р.Г., Стэг Ф.Г., Форд Й. от имени участников регистра CLARIFY. Ишемическая болезнь сердца. Современная реальность по данным всемирного регистра CLARIFY Кардиология. 2013;8:28-33. [Shalnova S.A., Oganov R.G., Steg F.G., Ford J. on behalf of participants of the register CLARIFY. Coronary heart disease. Modern reality according to the world register CLARIFY. Kardiologiia. 2013;8:28-33 (in Russ.)]
  9. Francis G.S. Neurohormonal control of heart failure. Clev. Clin. J. Med. 2011;78 (Suppl. 1):75-9.
  10. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N. Engl. J. Med. 1991;325:293-302.
  11. Cohn J.N., Johnson G., Ziesche S., Cobb F., Francis G., Tristani F., Smith R., Dunkman W.B., Loeb H., Wong M. et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N. Engl. J. Med. 1991;32:303-10.
  12. Con J.N., Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 2001;345:1667-75.
  13. Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П., Коротеев А.В., Мареев Ю.В., Овчинников А.Г., Беленков Ю.Н., Васюк Ю.А., Галявич А.С., Гарганеева А.А., Гиляревский С.Р., Глезер М.Г., Драпкина О.М., Козиолова Н.А., Коц Я.И., Лопатин Ю.М., Мартынов А.И., Моисеев В.С., Ревишвили А.Ш., Ситникова М.Ю., Скибицкий В.В., Соколов Е.И., Сторожаков Г.И., Фомин И.В., Чесникова А.И., Шляхто Е.В. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (4-й пересмотр). Сердечная недостаточность. 2013;7:379-472. [Mareev V.Yu., Ageev F.T., Artyunov G.P., Koroteeva A.V., Masreev Yu.V., Ovchinnikov A.G., Belenkov Yu.N., Vasyuk Yu.A., Galyavich A.S., Garganeeva A.A., Gilyarevsky S.R., Glezer M.G., Drapkina O.M., Koziolova N.A., Kots Ya.I., Lopatin Yu.M., Martynov A.I., Moiseev V.S., Revishvili A.Sh., Sitnikova M,Yu., Skibitsky V.V., Sokolov Ye.I., Storozhakov G.I., Fomin I.V., Chesnikova A.I., Shlyakhto Ye.V. National guidelines of Society for Heart Failure, the Russian Society of Cardiology and the Russian Scientific Medical Society of Physicians about how to diagnose and treat heart failure (4th revision). Heart failure. 2013;7:379-472 (in Russ.)]
  14. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., Palensky J., Wittes J.The effect of spironolactone on morbidity and mortality in patients with sever heart failure: Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 1999;341:709-17.
  15. Girerd N., Collier T., Pocock S., Krum H., McMurray J.J., Swedberg K., Van Veldhuisen D.J., Vincent J., Pitt B., Zannad F. Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial. Eur. Heart J. 2015;36(34):2310-7.
  16. Rossignol P., Ménard J., Fay R., Gustafsson F., Pitt B., Zannad F. Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. J. Am. Coll. Cardiol. 2011;58(19):1958-66.
  17. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., Bittman R., Hurley S., Kleiman J., Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 2003;348:1309-21.
  18. Cosin J., Diez J., on behalf of the TORIC investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur. J. Heart Failure. 2002;4:507-13.
  19. Мареев В.Ю., Выгодин В.А., Беленков Ю.Н. Диуретическая терапия эффективными дозами пероральных диуретиков торасемида (Диувер) и фуросемида в лечении больных с обострением хронической сердечной недостаточности (ДУЭЛЬ-ХСН). Сердечная недостаточность. 2011;1:3-10. [Mareev V.Yu., Vygodin V.A., Belenkov Yu.N. Diuretic therapy is effective oral doses of diuretics torasemide (Diuver) and furosemide in treating patients with acute exacerbation of chronic heart failure. (DUEL-KHSN). Heart failure. 2011;1:3-10 (in Russ.)]
  20. Struthers A.D., MacDonald T.M. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc. Rev. 2004;61:663-70.
  21. O'Gara P., Kushner F., Ascheim D., Casey D.E., Chung M.K., de Lemos J.A., Ettinger S.M., Fang J.C., Fesmire F.M., Franklin B.A., Granger C.B., Krumholz H.M., Linderbaum J.A., Morrow D.A., Newby L.K., Ornato J.P., Ou N., Radford M.J., Tamis-Holland J.E., Tommaso C.L., Tracy C.M., Woo Y.J., Zhao D.X. ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology Foundation/American Heart Association. Task force on practice guidelines. Circulation. 2013;127:e362-e425.
  22. Yancy C.W., Jessup M., Bozkurt B. et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation / American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 2013;62(16):147-239.
  23. Guichard J.L., Clark D. 3rd, Calhoun D.A., Ahmed M.I. Aldosterone receptor antagonists: current perspectives and therapies. Vasc. Health Risk Manag. 2013;9:321-31.
  24. Viengchareun S., Le Menuet D., Martinerie L., Munier M., Pascual-Le Tallec L., Lombes M. The mineralocorticoid receptor: insights into its molecular and (patho) physiological biology. Nucl. Recept Signal. 200730;5:e012.
  25. Aroor A.R., Demarco V.G., Jia G., Sun Z., Nistala R., Meininger G.A., Sowers J.R. The role of tissue renin-angiotensin-aldosterone system in the development of endothelial dysfunction and arterial stiffness. Front. Endocrinol. 2013;4:161.
  26. Yamato M., Sasaki T., Honda K., Fukuda M., Akutagawa O., Okamoto M., Hayashi T. Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circ. J. 2003;67:384-90.
  27. Goodfriend T.L., Ball D.L., Oelkers W., Bahr V. Torasemide inhibits aldosterone secretion in vitro. Life Sci. 1998;63:PL45-PL50.
  28. Uchida T., Yamanaga K., Nishikawa M., Kido H., Watanabe M. Anti-aldosteronergic effect of torasemide. Eur. J. Pharmacol. 1991;205:145-50.
  29. Uchida T., Yamanaga K., Kido H., Ohtaki Y., Watanabe M. Diuretic and vasodilating actions of torasemide. Cardiology. 1994;84 (Suppl. 2):14-7.
  30. Tsutamoto T., Wada A., Maeda K., Mabuchi N., Hayashi M., Tsutsui T., Ohnishi M., Sawaki M., Fujii M., Matsumoto T., Matsui T., Kinoshita M. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J. Am. Coll. Cardiol. 2001;37:1228-33.
  31. Lopez B., Querejeta R., Gonzalez A., Sanchez E., Larman M., Diez J. Effects of loop diuretics on myocardial fibrosis on chronic heart failure. J. Am. Coll. Cardiol. 2004;43:2028-35.
  32. Lopez B., Gonzalez A., Beaumont J., Querejeta R., Larman M., Diez J. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J. Am. Coll. Cardiol. 2007;50:859-67.
  33. Liguori A., Casini A., Di Loreto M., Andreini I., Napoli C. Loop diuretics enhance the secretion of prostacyclin in vitro, in health persons and in patients with chronic heart failure. Eur. J. Clin. Pharmacol. 1999;55:117-24.
  34. Yu H., Gallagher A.M., Garfin P.M., Printz M.P. Prostacyclin release by rat cardiac fibroblasts: inhibition of collagen expression. Hypertension, 1997;30:1047-53.
  35. Kasama S., Toyama T., Hatori T., Sumino H., Kumakura H., Takayama Y., Ichikawa S., Suzuki T., Kurabayashi M. Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure. Heart. 2006;92:1434-40.
  36. Muniz P., Fortuno A., Zalba G., Fortuno M.A., Diez J. Effects of loop diuretics on angiotensin II-stimulated vascular smooth muscle cell growth. Nephrol. Dial. Transplant. 2001;16 (Suppl. 1):14-7.
  37. Lopez B., Querejeta R., Gonzalez A., Beaumont J., Larman M., Diez J. Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure. Hypertension. 2009;53:236-42.
  38. Yamamoto К., Burnett J.C, Jougasaki M. et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension. 1996;28:988-94.
  39. Stroupe K.T., Forthofer M.M., Brater D.C., Murray M.D. Healthcare costs of patients with heart failure with torasemide or furosemide. Pharmacoeconomics. 2000;17(5):429-40.
  40. Young M., Plosker G.L. Torasemide: a pharmacoeconomic review of its use in chronic heart failure. Pharmacoeconomics. 2001;19(6):679-703.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies